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Active caspase-3CCR5-using (R5) human immunodeﬁciency virus type 1 (HIV-1) strains cause CD4+ T-cell loss in most
infected individuals, but mechanisms underlying cytopathicity of R5 viruses are poorly understood. We
investigated mechanisms contributing to R5 envelope glycoprotein (Env)-mediated cellular apoptosis by
constructing a panel of retroviral vectors engineered to co-express GFP and R5 Envs derived from two HIV-1-
infected subjects spanning asymptomatic (Early, E-R5 Envs) to late stages of infection (Late, L-R5 Envs). The
L-R5 Envs induced signiﬁcantly more cellular apoptosis than E-R5 Envs, but only in Env-expressing (GFP-
positive) cells, and only in cells where CD4 and CCR5 levels were limiting. Studies with fusion-defective Env
mutants showed induction of apoptosis required membrane-fusing events. Our results provide evidence for
an intracellular mechanism of R5 Env-induced apoptosis of CD4+ cells that requires membrane fusion.
Furthermore, they contribute to a better understanding of mechanisms involved in CD4+ T-cell loss in
subjects experiencing progressive R5 HIV-1 infection.
© 2009 Elsevier Inc. All rights reserved.Introduction
Progression of human immunodeﬁciency virus type 1 (HIV-1)
infection from early, asymptomatic stages of disease to acquired
immunodeﬁciency syndrome (AIDS) is associated with a switch in
viral coreceptor speciﬁcity from CCR5—using (R5) viral strains to
those able to use CXCR4 (X4) or both coreceptors (R5X4) in 40–50% of
infected adults (Bjorndal et al., 1997; Connor et al., 1997; Karlsson et
al., 1994a; Koot et al., 1993; Tersmette et al., 1989) [reviewed in (de
Roda Husman and Schuitemaker, 1998)]. However, X4 or R5X4
variants are absent in 50–60% of HIV-1 infected individuals who
progress to AIDS (de Roda Husman et al., 1999; Jansson et al., 1999;
Jansson et al., 1996; Karlsson et al., 2004; Koning et al., 2003)
[reviewed in (Gorry et al., 2004)]. Therefore, the persistence of an
exclusive R5 viral population in vivo is sufﬁcient to cause immuno-
deﬁciency in the majority of HIV-1 infected individuals who progress
to AIDS.et Institute, GPO Box 2284,
ll rights reserved.Whilst much is known about the molecular basis of pathogenicity
of late-emerging X4 and R5X4 viruses (Glushakova et al., 1995,
1998; Picchio et al., 1998) [reviewed in (de Roda Husman and
Schuitemaker, 1998)], the molecular mechanisms contributing to
pathogenicity of R5 HIV-1 strains are not entirely understood (Gorry
et al., 2004). R5 viruses are intrinsically cytopathic, but exert
pathogenic effects that are distinct from those of X4 or R5X4 viruses
(Fais et al., 1999; Grivel and Margolis, 1999; Harouse et al., 1999).
Compared to R5 HIV-1 strains isolated from asymptomatic indivi-
duals (referred to hereafter as “Early” or E-R5 viruses), R5 HIV-1
strains isolated from patients with late stages of infection (referred
to hereafter as “Late” or L-R5 viruses) have been reported to have
enhanced macrophage-tropism (Gray et al., 2005; Li et al., 1999;
Tuttle et al., 2002), increased viral ﬁtness (Borggren et al., 2008;
Repits et al., 2005, 2008), increased ability to scavenge low cellular
levels of CD4 and CCR5 for HIV-1 entry (Gray et al., 2005), reduced
sensitivity to HIV-1 entry inhibitors (Gray et al., 2005; Repits et al.,
2005) [reviewed in (Sterjovski et al., 2006)] and RANTES (Jansson et
al., 1999; Karlsson et al., 2004; Koning et al., 2003), and increased
sensitivity to the Env mAb IgG1b12 (Gray et al., 2005). Decreased
RANTES sensitivity has been attributed to an increased ﬂexibility of
the R5 envelope glycoproteins (Env) that subsequently alters the
Table 1
Characteristics of primary R5 viruses and Env clones.
Virusa Descriptionb Env clonec Coreceptor usaged
CCR5 CXCR4
IK1-E E-R5 IK1-E-1 ++ −
IK1-E-2 + −
IK1-L L-R5 IK1-L-1 ++ −
IK1-L-2 +++ −
IK2-E E-R5 IK2-E-1 + −
IK2-E-2 ++ −
IK2-L L-R5 IK2-L-1 ++ −
IK2-L-2 +++ −
Control Envs
ΔKS Env − −
HXB2 Env − +++
89.6 Env +++ +++
ADA Env +++ −
JRCSF Env +++ −
YU2 Env +++ −
a The phenotypes of the primary R5 HIV-1 isolates, and clinical characteristics of the
subjects from whom they were isolated have been described in detail previously
(Jansson et al., 1999; Karlsson et al., 1994b, 2003, 2004).
b E-R5, Early R5 HIV-1 isolate; L-R5, Late stage R5 HIV-1 isolate.
c Functional Env clones were identiﬁed by infection of JC53 cells with Env-
pseudotyped GFP reporter viruses and by fusion assays, as described in Materials and
Methods (data not shown).
d Coreceptor usage of functional Envs was determined by infection of Cf2-CD4/
CCR5 and Cf2-CD4/CXCR4 cell lines with Env-pseudotyped GFP-reporter viruses, as
described in Materials and methods. The coreceptor usage of Envs derived from
viruses IK1-E and IK1-L has been described previously (Sterjovski et al., 2007). GFP
positive cells were counted manually by ﬂuorescence microscopy and scored as− (no
GFP positive cells), +/− ( 1 to 5% GFP positive cells),+ (5 to 10% GFP positive cells),
++ (10 to 30% GFP positive cells), or +++ (N30% GFP positive cells).
247J. Wade et al. / Virology 396 (2010) 246–255mode and efﬁciency of CCR5 binding (Karlsson et al., 2004). Further
studies of R5 Envs cloned from E-R5 and L-R5 viruses showed L-R5
Envs have enhanced CCR5-dependent fusogenicity and faster HIV-1
entry kinetics, and are more likely to exist in conformations that
promote greater exposure or stabilization of the CD4 binding site
(CD4bs) in gp120 (Sterjovski et al., 2007). Together, these ﬁndings
provide evidence that L-R5 viruses have intrinsic properties
distinguishing them from E-R5 viruses which may enhance their
cytopathic effects, and that these properties are likely to be linked to
Env conformations that enhance CD4 and/or CCR5 interactions.
In addition to receptor binding and mediating HIV-1 entry, Env is
responsible for the cytopathic effects of HIV-1 infection in cultured
cells (Sodroski et al., 1986), andmay contribute to death of uninfected
cells through bystander mechanisms (Holm et al., 2004). Further-
more, passage of chimeric simian-HIV (SHIV) strains in macaques
demonstrated enhancement of pathogenicity that was associated
with mutations in Env (Cayabyab et al., 1999; Karlsson et al., 1997,
1998; Liu et al., 1999; Stephens et al., 1996; Stephens et al., 1997),
which often resulted in increased Env-mediated cytopathicity
(Etemad-Moghadam et al., 2000, 2001; Karlsson et al., 1998; Liu et
al., 1999; Si et al., 2004). Together, these studies suggest that
alterations in the HIV-1 Env which augment cytopathicity may
contribute to CD4+ T-cell loss during progressive HIV-1 infection.
To determine whether Env mediated cytopathicity increases
during progressive R5 HIV-1 infection, we characterized E-R5 and L-
R5 Envs cloned from sequential viruses isolated from two individuals
who experienced progressive HIV-1 infection whilst harboring R5
HIV-1 variants. Our results show that L-R5 Envs from both subjects
induced signiﬁcantly more cellular apoptosis than E-R5 Envs when
delivered intracellularly by retroviral transduction, but only in cells
where CD4 and CCR5 levels were limiting, and only in Env-expressing
cells. Env-mediated bystander apoptosis was not evident in this
system. These results provide evidence for an intracellular mechanism
of R5 Env-induced apoptotic cell death requiring membrane fusion
which, in some individuals may contribute to CD4+ T-cell loss during
progressive R5 HIV-1 infection.
Results
Biological activities of primary R5 HIV-1 Env clones
To better understand Env determinants involved in progressive R5
HIV-1 infection, we produced a longitudinal panel of E-R5 and L-R5
Envs cloned from two subjects, IK1 and IK2, spanning asymptomatic
through to late stage HIV-1 infection. The Envs from subject IK1 used
in this study, IK1-E-1 and -2 and IK1-L-1 and -2, have been reported
previously (Sterjovski et al., 2007) and were conﬁrmed to be
functional and of R5 phenotype in single-round HIV-1 entry assays
and fusion assays (Table 1), and shown to process gp120 efﬁciently
from gp160 in transfected cells by Western blotting (Sterjovski et al.,
2007). In order to expand this set of longitudinal R5 Envs to include
those from another subject, Envs were cloned from E-R5 and L-R5
viruses isolated from subject IK2 (Karlsson et al., 2004) into the
pSVIIIEnv expression vector. Two independent, functional and
properly processed Envs cloned from each virus were identiﬁed by
single round entry assays in JC53 cells using Env-pseudotyped GFP
reporter viruses, fusion assays, and Western blotting (Table 1, and
data not shown). To conﬁrm the coreceptor speciﬁcity of the cloned
Envs, Env-pseudotyped GFP reporter viruses were used in single
round entry assays with Cf2th cell lines stably expressing CD4/CCR5
or CD4/CXCR4 (Table 1). The X4 HXB2, R5X4 89.6 and R5 ADA, JRCSF
and YU2 Envs were used as positive controls. A non-functional Env,
ΔKS Env, was used as a negative control to determine background
levels of GFP expression. All Envs from subjects IK1 and IK2 used CCR5
for HIV-1 entry, similar to the coreceptor speciﬁcity of the primary
isolates from which they were cloned. Thus, we established andvalidated a longitudinal panel of eight functional E-R5 and L-R5 Envs
derived from two subjects with progressive R5 HIV-1 infection.
Utility of GFP expression from psrHIVenvGFP vectors as a surrogate for
Env expression in transduced cells
Previous studies showed that Env could be detected in every GFP-
positive (GFP+) cell following transduction of cell cultures with the
X4 HXB2 Env using recombinant viruses encoding psrHIVenvGFP
vectors (LaBonte et al., 2000), indicating that in this retroviral
transduction system GFP can be used as a simple, non-disruptive
and reliable way to determine which cells in a transduced population
are and are not expressing Env. Nonetheless, we wished to validate
the reliability of GFP as a surrogate for R5, X4 and R5X4 Env
expression, and to conﬁrm whether Envs with these phenotypes are
correctly processed in transduced cells. JC53 cells were transduced
with equivalent titers of replication-defective viral vectors expressing
X4 HXB2, R5X4 89.6 or R5 ADA Envs, or the ΔEnvmutant as a negative
control, and 48 h later were ﬁxed and permeabilized, and examined
for GFP and Env expression using ﬂuorescence microscopy (Fig. 1A).
In the cultures transducedwith X4, R5X4 or R5 Envs, Envwas detected
in every GFP+ cell and vice versa. In JC53 cells transduced to express
the ΔEnv mutant, many GFP+ cells were present but none stained
with the primary and secondary antibodies used to detect Env,
indicating their speciﬁcity for Env. Further experiments comparing
permeabilized to non-permeabilized cells showed that the vast
majority of detectable Env staining was intracellular, and the small
amounts of cell surface-detectable Env were evident in only a
proportion of GFP+ cells (Supplementary Fig. 1). Consistent with
this observation, the majority of the GFP+ cells remained as single
cells (Fig. 1A and Supplementary Fig. 1), although some syncytia
were evident. Transduced JC53 cells were also lysed and analyzed
for gp160/gp120 expression by Western blotting at 48 h post-
transduction (Fig. 1B). In the cultures transduced with X4, R5X4 or R5
Envs, gp120 bands were detected indicating correct processing of
gp160 to gp120. Thus, we conﬁrmed that GFP expression is a reliable
Fig. 1. Coexpression of GFP and Env in transduced cells and gp120 production. (A) JC53 cells were transduced with psrHIVenvGFP vectors encoding HXB2, 89.6 or ADA Env, or with
psrHIVΔenvGFP. At 48 h post-transduction cells were ﬁxed and permeabilized, labeled with the human polyclonal antibody BB10 that is strongly reactive for Env protein but is not
reactive against HIV-1 regulatory/accessory proteins (Gorry et al., 1998, 1999) and Texas Red-conjugated anti-human antibody. Cells were analyzed for GFP (left panel) or Env
expression (middle panel). The merged images (right panel) show that every GFP-expressing cell also expresses HXB2, 89.6 or ADA Env protein. Note that in cells transduced with
the psrHIVΔenvGFP vector, GFP-expressing cells are present but they do not stain with the primary and secondary antibodies, indicating the speciﬁcity of these antibodies for Env in
cells transduced with psrHIVenvGFP vectors. Each image is one z section from the deconvolved z-stack image. The micrographs shown are representative of 5 random ﬁelds of one
experiment and are of ×600 ﬁnal magniﬁcation. (B) Env expression in lysates of transduced JC53 cells was measured by Western blot analysis using rabbit anti-gp120 polyclonal
antisera, as described in Materials and methods. The positions of gp160 and gp120 are indicated on the right.
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expressed from psrHIVenvGFP vectors, and that in this system Env
expression is predominantly intracellular.
Direct and bystander cellular apoptosis by prototypic R5 Envs
Previous studies have characterized cytolysis induced by the R5
ADA Env in cells after transduction with psrHIVenvGFP vectors using
non-speciﬁc measures such as cell viability assays and syncytia
formation (LaBonte, Madani, and Sodroski, 2003), but whether
cytolysis from intracellular ADA Env expression was due to apoptosis
or other mechanisms, or whether Env-mediated cytolysis is a
phenotype of other R5 Envs, is unknown. To determine whether
ADA and other prototypic R5 Envs cause apoptotic cell death
following transduction with psrHIVenvGFP vectors, JC53 and PM1
cells were transduced with vectors expressing the R5 ADA, JRCSF or
YU2 Envs. Cells transduced with the ΔEnv construct were included
to control for the effects of non-Env elements in the transducing
viruses. JC53 and PM1 cells were used because they are cell lines
that express both CD4 and CCR5 and are permissive to R5 HIV-1
infection. Cells were harvested at 24, 48, 72 and 96 h post-
transduction and stained for active caspase-3 expression, whichwas quantiﬁed separately by ﬂow cytometry in GFP+(i.e., Env-
expressing) and GFP-negative (GFP-) (i.e., Env-negative) cell
populations to determine the level of direct and bystander cell
apoptosis, respectively (Fig. 2). The total cell numbers, individual
transduction percentages, and total numbers of GFP+ and GFP-cells
analyzed in these and subsequent experiments are summarized in
Supplementary Table 1. Representative ﬂow cytometry data from
which Fig. 2 was derived are shown in Supplementary Fig. 2. In JC53
and PM1 cells, each of the R5 Envs induced apoptosis in more than
80% or 40% of GFP+ cells by 96 h post-transduction, respectively.
This was comparable to the levels of apoptosis mediated by the X4
HXB2 and R5X4 89.6 Envs in GFP+ populations of both cell types
(data not shown). Background levels of apoptosis that did not
exceed 10% of GFP+ cells were observed in cells transduced with
the ΔEnv construct, indicating that the increases in apoptosis
observed were due to Env. In both cell types, cellular apoptosis in
GFP-cell populations was not measured above background levels,
indicating that bystander apoptosis was not evident in this system.
These results indicate that diverse R5 Envs may cause signiﬁcant
levels of apoptosis in Env expressing cells, similar to X4 and R5X4
Envs, and that JC53 cells are more permissive to Env-mediated
apoptosis than PM1 cells.
Fig. 2. Direct and bystander cellular apoptosis by prototypic R5 Envs. JC53 (left panels) or PM1 cells (right panels) were transduced with psrHIVenvGFP vectors encoding R5 JRCSF,
ADA or YU2 Envs, or with psrHIVΔenvGFP as a negative control as described in Materials and methods. At the indicated times after transduction, cells from independent duplicate
cultures were harvested, ﬁxed and permeabilized, and labeled with an anti-human active caspase-3 antibody and PE-conjugated anti-rabbit IgG as described in Materials and
methods. The percentage of GFP+(Env-expressing) and GFP-(Env-negative) cells that stained positive for active caspase-3 expression was determined by ﬂow cytometry. The data
shown are means of duplicate wells, and the error bars represent standard deviations.
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cells
To better understand the molecular mechanisms involved in
activation of the caspase-3 pathway in Env-expressing cells, PM1 cells
were transduced with vectors expressing the R5 ADA, X4 HXB2 or
R5X4 89.6 Envs in parallel with fusion-defective F/Y mutants (Fig. 3).
Compared to the parental Envs, these fusion-defective mutants
express equivalent amounts of properly processed gp120 and retain
the ability to bind CD4 and coreceptor, but they cannot mediate
membrane fusion (LaBonte et al., 2000, 2003) (and data not shown).
Although apoptosis was induced in the majority of GFP+ cells
expressing ADA, HXB2 or 89.6 Envs by 72 h post-transduction,
background levels of apoptosis were observed in cells expressing the
respective fusion-defective Env mutants. Thus, activation of the
caspase-3 pathway by Env is dependent on membrane fusing activity,
and this appears to be a common requirement of Envs with diverse
phenotypes.
Direct and bystander cellular apoptosis by primary E-R5 and L-R5 Envs
To determine whether primary R5 Envs isolated from individuals
with asymptomatic or late stages of HIV-1 infection differ in their
ability to induce cellular apoptosis, the KpnI-to-BamHI region of pSVIIIEnvs encoding E-R5 and L-R5 Envs of subjects IK1 and IK2 (Table 1)
was cloned into psrHIVenvGFP vectors, and equivalent titers of
recombinant virus was used to transduce JC53 and PM1 cells (Fig. 4).
In JC53 cells, all of the primary R5 Envs induced apoptosis in more
than 90% of GFP+ cells by 96 h post-transduction. There was no
accumulation of apoptosis in GFP-cells, indicating that apoptosis was
conﬁned to Env-expressing cells. In both subjects, there was no
difference in the levels of cellular apoptosis in JC53 cells between E-R5
and L-R5 Envs. In PM1 cells, the L-R5 Envs from both subjects induced
apoptosis in 40 to 60% of GFP+ cells at 72 h post-transduction which
decreased marginally by 96 h, whereas the E-R5 Envs from both
subjects induced apoptosis in only 10 to 25% of GFP+ cells. There was
no accumulation of apoptosis in GFP-cells, similar to the results using
JC53 cells. The overall levels of Env expression and gp120 processing
by the E-R5 and L-R5 Envs were similar (data not shown). These
results indicate that, in both subjects, L-R5 Envs induce greater levels
of apoptosis than E-R5 Envs when expressed in PM1 cells, but not
when expressed in JC53 cells.
Sequence analysis
To better understand Env determinants contributing to the
increased ability of L-R5 Envs to induce apoptosis in PM1 cells, the
unique KpnI-to-BamHI region of gp160 was sequenced and analyzed
Fig. 3. The requirement of membrane fusion for cellular apoptosis by diverse Envs. PM1
cells were transduced with psrHIVenvGFP vectors encoding HXB2, 89.6 or ADA Envs in
parallel with their respective fusion-defective F/Ymutants, or with psrHIVΔenvGFP as a
negative control as described in Materials and methods. At the indicated times after
transduction, cells from independent duplicate cultures were harvested, ﬁxed and
permeabilized, and labeled with an anti-human active caspase-3 antibody and PE-
conjugated anti-rabbit IgG as described in Materials and methods. The percentage of
GFP+(Env-expressing) and GFP-(Env-negative) cells that stained positive for active
caspase-3 expression was determined by ﬂow cytometry. The data shown are means of
duplicate wells, and the error bars represent standard deviations.
250 J. Wade et al. / Virology 396 (2010) 246–255for amino acid changes which may inﬂuence Env function. The E-R5
and L-R5 Envs could not be segregated based on the total number of
potential N-linked glycosylation sites (PNGS) in gp120 and gp41,
nor when numbers of PNGS were stratiﬁed across the V1V2, V4 or
V5 regions of gp120 (data not shown). The net charge of the V3
region of gp120 was+3 or+4, which is typical of HIV-1 subtype B
R5 Envs (Briggs et al., 2000; Milich et al., 1993), and V3 charge did
not segregate E-R5 from L-R5 Envs. There was no clear signature
pattern that unambiguously segregated E-R5 from L-R5 Envs that
was common to both subjects, suggesting that Env sequence
alterations contributing to enhancement of apoptosis in PM1 cells
are likely to be patient-speciﬁc and/or context dependent. There
were numerous patient-speciﬁc single amino acid changes which
segregated E-R5 from L-R5 Envs that could potentially inﬂuence Env
function (see Supplementary Table 2). These include conserved
changes in the C1, V1, V2, C2, V3, C3, V4 and V5 region of gp120,
some of which resulted in alterations in glycosylation patterns or
alterations in the CD4bs, and within gp41. Further studies are
required to better understand the signiﬁcance of these amino acid
alterations in modulating the ability of R5 Envs to cause apoptosis
in PM1 cells.Discussion
In this study, we generated and characterized a panel of E-R5 and
L-R5 Envs cloned from sequential viruses isolated from two
individuals who experienced progressive HIV-1 infection whilst
harboring R5 HIV-1 variants. Our results show that L-R5 Envs from
both subjects induced greater levels of cellular apoptosis that E-R5
Envs when delivered intracellularly by retroviral transduction, but
only in PM1 cells where CD4 levels were limiting, and only in Env-
expressing cells. The expression levels of CD4 and CCR5 in PM1 cells
are similar to those in primary CD4+ T-cells, whereas JC53 cells over-
express both receptors (data not shown). Thus, expression of Env in
PM1 cells from psrHIVenvGFP vectors is a validmodel for studying the
activity of Env expressed during HIV-1 infection in CD4+ cells.
Our studies with fusion-defective F/Y Env mutants indicate that
binding of gp120 to CD4 and coreceptor is not sufﬁcient to activate
caspase-3 dependent apoptosis in Env-expressing cells. The ability to
induce apoptosis was dependent on the membrane fusing activity of
the Envs. These results support and extend previous studies that
examined the role of F/Y Env mutants on Env-mediated cytopathicity
using non-speciﬁc measures of cell viability (LaBonte et al., 2000,
2003). Passage of SHIV strains in macaques demonstrated enhance-
ment of pathogenicity that was associated with Env mutations which
enhanced fusogenicity (Etemad-Moghadam et al., 2001, 2000;
Karlsson et al., 1998; Liu et al., 1999; Si et al., 2004), suggesting that
increased membrane fusing activity of Env contributes to viral
pathogenicity in this animal model. In addition, compared to E-R5
HIV-1 Envs, the L-R5 Envs from subject IK1 as well as those from a
cross-sectional cohort of individuals have enhanced CCR5-mediated
fusogenicity (Sterjovski et al., 2007), suggesting that enhanced
membrane fusing activity of Env may contribute to loss of CD4+ T-
cells in subjects with progressive R5 HIV-1 infection. Furthermore, in
the cross-sectional study of L-R5 Envs, enhanced fusogenicity resulted
from enhanced exposure or stabilization of the CD4bs in gp120
(Sterjovski et al., 2007). Because the retroviral constructs used in the
present studywere designed to express Env in a similar context to that
from the native HIV-1 RNA, the levels of Env expressed are similar to
those in HIV-1 infected cells, and expression of Env is predominantly
intracellular (LaBonte et al., 2000). Thus, in our studies the induction of
apoptosis seems to occur through an intracellular mechanism. Taken
together, these studies suggest that in PM1 cells, L-R5 Envs may have
an increased ability to interactwith relatively low intracellular pools of
CD4 than E-R5 Envs, with subsequent fusion and disruption of internal
membranes leading to apoptosis. The reliance on Env-mediated fusion
suggests a putative role of gp41 in this process. Further studies with
cells engineered to express different levels of CD4 are required to test
the hypothesis that Env-mediated apoptosis of Env-expressing cells
occurs through a CD4-dependent mechanism.
However, our results are inconsistent with those of a previous study,
which showed that higher levels of CD4 expression protected cells from
Env-mediated cell death (LaBonte et al., 2003). In this study, high CD4
levels expressed in the Cf2th canine thymocyte cell line sequestered Env
intracellularly and abrogated processing of gp160 to gp120 and hence,
reduced Env-mediated cell death. In our study JC53 cells, which express
higher levels of CD4 than the CD4-expressing Cf2th cell line used in the
previous study, were highly sensitive to Env-mediated apoptosis, even
more so than PM1 cells which expressed much lower levels of CD4. In
addition, gp120 was correctly processed when expressed from the
psrHIVenvGFP vectors in JC53 cells (Fig. 1B). Thus, high CD4 levels did
not prevent Env-mediated apoptosis in our study. Biological differences
between the human cell lines used in our study and the canine cell lines
used previously (LaBonte et al., 2003), and differences between the
assays used to measure cell death (active caspase-3 staining versus cell
viability and syncytia formation) may explain these discrepancies.
In cells transduced with psrHIVenvGFP vectors, cellular apoptosis
occurred only in Env-expressing cells and not in bystander cells. This
Fig. 4. Direct and bystander cellular apoptosis by primary E-R5 and L-R5 Envs. JC53 (left panels) or PM1 cells (right panels) were transduced with psrHIVenvGFP vectors encoding
primary E-R5 or L-R5 Envs derived from subjects IK1 and IK2, or with psrHIVΔenvGFP as a negative control as described in Materials and methods. At the indicated times after
transduction, cells from independent duplicate cultures were harvested, ﬁxed and permeabilized, and labeledwith an anti-human active caspase-3 antibody and PE-conjugated anti-
rabbit IgG as described in Materials and methods. The percentage of GFP+(Env-expressing) and GFP-(Env-negative) cells that stained positive for active caspase-3 expression was
determined by ﬂow cytometry. The data shown are means of duplicate wells, and the error bars represent standard deviations.
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does not involve cytotoxicity of cells surrounding those expressing
Env. Previous studies have shown that Env-mediated bystander
apoptosis may occur in cellular systems using transfection to over-
express Env or with cell lines constitutively overexpressing Env
(Algeciras-Schimnich et al., 2002; Garg and Blumenthal, 2006; Garg et
al., 2007), infection with cell-free virions (Holm et al., 2004; Jacotot et
al., 1997; Jekle et al., 2003), treatment with non-replicating virions
(Holm et al., 2004), or soluble gp120 (Trushin et al., 2007), suggesting
that death of bystander cells may occur when the cell exterior is
exposed to Env or when Env is overexpressed on the cell surface. Our
results suggest that bystander apoptosis is not likely to occur by Env
expressed within single HIV-1 infected cells when expressed from the
native HIV-1 RNA. However, this conclusion does not exclude the
possibility that bystander cells may be destroyed when incorporated
into syncytia or through hemifusion events when Env is expressed at
higher levels or when cells are cultured at higher density. As
hemifusion events are difﬁcult to detect by ﬂow cytometry, further
studies using immunoﬂuorescence are required to determine wheth-
er bystander apoptosismay occur in cells undergoing hemifusionwith
cells transduced with Env-expressing recombinant viruses. Indeed,
hemifusion has been well described in cell-cell coculture systems
using effector cells overexpressing Env on the cell surface and CD4+
T-cell targets [reviewed in (Garg and Blumenthal, 2008; Jacobs et al.,2008; Perfettini et al., 2005)]. Consistent with our results which
highlight the dependence of Env-mediated fusion for apoptosis of
Env-expressing cells, these studies showed that Env-mediated
apoptosis of bystander cells through hemifusion was induced by
gp41 (Garg and Blumenthal, 2006; Garg et al., 2007), and is inﬂuenced
by the fusogenic properties of Env (Garg et al., 2009).
In conclusion, L-R5 Envs from two subjects with progressive R5
HIV-1 infection induced greater levels of cellular apoptosis than E-R5
Envs isolated from the same subjects during asymptomatic stages of
HIV-1 infection, but only in Env-expressing cells, and only in cells
where HIV-1 receptor levels were limiting and comparable to primary
CD4+ T-cells. Further studies are required to conﬁrm these results in
the setting of viral replication. Our results showed that Env-mediated
apoptosis depends on the fusion activity of Env. Increased apoptotic
death of HIV-1 infected cells may contribute to CD4+ T-cell loss in
subjects who experience progressive infection whilst harboring R5
HIV-1 variants.
Materials and methods
Virus isolates
In this study, we utilized a longitudinal panel of R5 HIV-1 viruses
isolated sequentially from two subjects from asymptomatic (n=2
252 J. Wade et al. / Virology 396 (2010) 246–255isolates) to late stages of HIV-1 infection (n=2 isolates). For the
purpose of this study, the viruses isolated frompatientswith late stage
HIV-1 infection are referred to as L-R5 viruses, and those isolated from
the earlier times are referred to as E-R5 viruses. Viruses were isolated
from sequential PBMC samples from subjects IK1 and IK2 and are
designated IK1-E, IK1-L, IK2-E and IK2-L, respectively. The virus
isolates were referred to previously as 435–531, 435–3415, 1047–314,
and 1047–7418, respectively (Karlsson et al., 2004). The E-R5 isolates
were obtained when both subjects had CD4+ T-cell counts of N600
cells/μl (50 and 41 months after infection for subjects IK1 and IK2,
respectively), and the L-R5 isolates were obtained when both subjects
were experiencing sustained immunological failure with CD4+ T-cell
counts b300 cells/μl (95 and 130 months after infection for subjects
IK1 and IK2, respectively) (Karlsson et al., 2004). A detailed
characterization of the HIV-1 isolates including analysis of quasispe-
cies diversity, coreceptor usage, replication kinetics, and clinical
characteristics of the subjects from whom they were isolated, has
been described previously (Jansson et al., 1999; Karlsson et al., 1994b,
2003, 2004).
Cells
JC53 cells are derived from the HeLa cell line and stably express
high levels of CD4, CXCR4 and CCR5 on the cell surface (Platt et al.,
1998), and were cultured in DMEM supplemented with 10% (vol/vol)
fetal calf serum (FCS), and 100 μg of penicillin and streptomycin per
ml. Cf2-CD4/CCR5 cells (Yang et al., 2004) were cultured in DMEM
supplemented with 10% (vol/vol) FCS, 100 μg of penicillin and
streptomycin perml, 0.5mg of G418 perml, and 0.1mg of hygromycin
per ml. Cf2-CD4/CXCR4 cells were constructed by transduction of the
Cf2-CD4 cell line (Xiang et al., 2005) with pBABE-puro vectors
expressing CXCR4 (Deng et al., 1997; Morgenstern and Land, 1990)
followed by selection and expansion in DMEM supplemented with
10% (vol/vol) FCS, 100 μg of penicillin and streptomycin perml, 0.5mg
of G418 per ml, and 1 μg of puromycin per ml. PM1 cells were cultured
in RPMI 1640 medium supplemented with 10% (vol/vol) FCS, and
100 μg of penicillin and streptomycin per ml. 293T cells were cultured
in DMEM supplemented with 10% (vol/vol) FCS, and 100 μg of
penicillin and streptomycin per ml.
PCR ampliﬁcation, HIV-1 Env cloning, identiﬁcation of functional Envs,
and sequence analysis
The cloning of HIV-1 Envs derived from viruses IK1-E and IK1-L
into the pSVIII-Env expression plasmid and their functional charac-
terization including expression levels, gp120 processing and core-
ceptor usage has been described in detail previously (Sterjovski et al.,
2007). Functional Envs were similarly cloned from viruses IK2-E and
IK2-L. Brieﬂy, viral RNA was isolated using a QIAmp UltraSense viral
RNA isolation kit (Qiagen, Venlo, The Netherlands), according to the
manufacturers' instructions. cDNA was reversed transcribed from
viral RNA using SuperscriptIII RT (Invitrogen, Carlsbad, CA) and
random hexamers, according to the manufacturers' protocol. An
approximately 2.1 kb fragment spanning the KpnI to BamHI restriction
sites in HIV-1 env (corresponding to nucleotides 6348 to 8478 in
HXB2) was ampliﬁed by PCR using nested primers and Expand high
ﬁdelity DNA polymerase (Roche diagnostics, Basle, Switzerland). The
outer primers were env1A and env1 M (Gao et al., 1996), and the
inner primers were Env-KpnI and Env-BamHI (Gray et al., 2006;
Ohagen et al., 2003). PCR cycling consisted of an initial denaturation
step at 94 °C for 2 min followed by 9 cycles of 94 °C for 15 s, 60 °C for
30 s and 72 °C for 2min, then a further 20 cycles of 94 °C for 15 s, 60 °C
for 30 s and 72 °C for 2min but with a 5 s increasing extension time for
each cycle, followed by a ﬁnal extension at 72 °C for 7 min. The
products of 3 independent PCR reactions were puriﬁed and pooled,
then cloned into the pSVIII-HXB2 Env expression plasmid byreplacement of the 2.1 kb KpnI to BamHI HXB2 env fragment. Thus,
the resulting Env clones contain the entire gp160 coding region of
primary virus-derived env genes except for 36 amino acids at the N
terminus and 105 amino acids at the C terminus, which are derived
from HXB2. Functional Env clones were identiﬁed by the ability to
support entry when pseudotyped onto Env-deﬁcient GFP reporter
viruses and used in single round entry assays in JC53 or Cf2-CD4/
CCR5/CXCR4 cells, and by Western blot analysis of gp120/gp160 in
transfected 293T cells and fusion assays. The coreceptor usage of
functional Env clones was veriﬁed by single round entry assays in Cf2-
CD4/CCR5 and Cf2-CD4/CXCR4 cells infected with Env-pseudotyped
GFP reporter viruses, as described previously (Gray et al., 2006; Gray
et al., 2009; He et al., 1997; Sterjovski et al., 2007). Envs were
sequenced by Big Dye terminator sequencing (Applied Biosystems,
Carlsbad, CA) and analyzed using a model 3100 Genetic Analyzer
(Applied Biosystems).
Viral vectors
The construction and characterization of the replication-defective
psrHIVenvGFP vector, which expresses HIV-1 Env from a LTR
promoter together with GFP from an IRES element, has been described
in detail previously (LaBonte et al., 2000). In addition to Env and GFP,
this vector expresses the HIV-1 Tat, Rev and Vif proteins and a C-
terminally truncated, functionally defective Vpr protein derived from
theHXBc2 strain of HIV-1. psrHIVenvGFP vectors containing the 2.1 kb
KpnI to BamHI fragments of HXB2 or 89.6 Envs, or fusion-defective
F/Y mutants of HXB2, 89.6 or ADA Envs in which phenylalanine at
amino acid position 522 in each of these Envs was changed to tyrosine
by PCR site directed mutagenesis have been described previously
(LaBonte, Madani, and Sodroski, 2003; LaBonte et al., 2000) and were
kindly provided by Dr Joseph Sodroski, Dana-Farber Cancer Institute,
Boston. psrHIVenvGFP vectors containing Envs derived from the R5
ADA, JRCSF or YU2 strains of HIV-1, or one of eight different functional
Envs derived from the primary R5 viruses IK1-E, IK1-L, IK2-E or IK2-L
(clones IK1-E-1 and -2, IK1-L-1 and -2, IK2-E-1 and -2, and IK2-L-1
and -2, respectively) were constructed by replacing the 2.1 kb KpnI to
BamHI fragment of psrHIVenvGFP with the corresponding fragments
of pSVIII-Env plasmids encoding these Envs. The psrHIVΔenvGFP
plasmid (LaBonte et al., 2000), which contains a deletion mutation in
the env gene with an intact Rev-responsive element, and is otherwise
isogenic to psrHIVenvGFP, was used as a negative control vector in the
subsequent transduction studies to control for the effects of non-Env
vector elements.
Production of recombinant viruses
Replication-defective, Env-expressing transducing viruses pseu-
dotyped with the vesicular stomatitis virus (VSV) G protein were
produced by cotransfecting 293T cells with psrHIVenvGFP plasmid
together with pCMVΔP1ΔenvpA, pCMV-G and pCMV-Rev (which all
lack HIV-1 packaging signals and supply the HIV-1 gag, and pol gene
products, the VSV G protein, and the HIV-1 Rev protein under the
control of the cytomegalovirus immediate-early promoter, respec-
tively, in trans), at a ratio of 10:10:2:1, as described previously
(LaBonte et al., 2000). Transfections were performed using
Lipofectamine 2000 (Invitrogen), according to the manufacturer's
instructions. At 48 h post-transfection conditioned medium contain-
ing recombinant viruses was harvested, ﬁltered through 0.45 μm
ﬁlters, and stored in 1 ml aliquots at −80 °C.
Titration of recombinant viruses
The recombinant viruses were titrated on JC53 or PM1 cells, to
determine an appropriate dilution to achieve approximately 5–10%
transduction efﬁciency in each cell type. Sub-conﬂuent monolayers of
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of 5×105 cells/ml in 24-well plates, were transduced for 16 h with
serial dilutions of each recombinant virus whilst maintaining a
constant total volume of culture medium, after which the medium
was changed and the cells were incubated for a further 48 h at 37 °C.
The cells were then collected, washed in phosphate-buffered saline,
ﬁxed in 4% (wt/vol) paraformaldehyde and analyzed for GFP
expression using a Becton Dickinson FACSCalibur ﬂow cytometer.
Transduction of cells and active caspase-3 staining
JC53 or PM1 cells were cultured in duplicate wells of 24-well plate
as described above, and transduced with a sufﬁcient titer of
recombinant virus to achieve infection of approximately 5–10% of
cells. These culture conditions were found to be optimal for ensuring
that the majority of the cells transduced with Env and GFP remain as
single cells and not syncytia (LaBonte et al., 2000). After 16 h the
culture medium was changed, and cells from duplicate transductions
were harvested 24, 48, 72 and 96 h later for analysis of active caspase-
3. At these timepoints, cells were washed in PBS and then ﬁxed and
permeabilized with 100 μl cytoﬁx-cytoperm solution (Pharmingen,
San Diego, CA.) for 30 min at 4°. After washing twice with perm/wash
buffer (Pharmingen), the cells were blocked with 1% (wt/vol) bovine
serum albumin (BSA) followed by incubation with a 1:250 dilution of
anti-human active caspase-3 antibody (Promega, Madison,WI) for 1 h
at room temperature. Cells were washed twice with perm/wash
buffer (Pharmingen) and then incubated with PE-conjugated F' (ab)
anti-rabbit IgG antibody (Rockland Immunochemicals) for 45 min at
room temperature. Cells were then washed twice with PBS,
resuspended in 200 μl PBS and analyzed for GFP and active caspase-
3 expression by ﬂow cytometry.
Immunoﬂuorescence
JC53 cells were cultured on chamber slides (ibidi, Munich,
Germany) and transduced with recombinant virus expressing HXB2,
89.6 or ADA Env. Cells transduced with recombinant virus expressing
the Env mutant (ΔEnv) were included as a negative control for
detection of Env expression. At 48 h post-transduction, the slides were
washed in PBS, ﬁxed and permeabilized in PBS containing 4% (wt/vol)
paraformaldehyde and 0.1% (vol/vol) Triton-X100 for 30 min at room
temperature, and blocked in PBS containing 1% (wt/vol) BSA and 5%
(vol/vol) normal goat serum (Chemicon, Temecula, CA), for 90 min at
room temperature. Cells were then incubated with a 1:200 dilution of
BB10 antisera in PBS containing 1% (wt/vol) BSA and 0.5% (vol/vol)
Tween-20 for 1 h at room temperature. BB10 is reactive against HIV-1
Env and Gag proteins but is not reactive against HIV-1 regulatory/
accessory proteins (Gorry et al., 1998, 1999). Thus, in the transduc-
tions BB10 antisera is speciﬁc for HIV-1 Env. Cells transduced with
recombinant virus expressing the ΔEnv mutant were included to
conﬁrm the speciﬁcity of BB10 for Env in these experiments. Cells
were thenwashed 5 times in PBS containing 0.5% (vol/vol) Tween-20,
and then incubated with a 1:500 dilution of Texas Red-conjugated
anti-human antibody in PBS containing 1% (wt/vol) BSA and 0.5%
(vol/vol) Tween-20 for 45 min at room temperature. Cells were
washed in PBS and images were captured in a z series on a charge-
coupled device camera (CoolSnap HQ, Photometrics) through a
60×1.42 numerical aperture oil immersion lens on a DeltaVision
microscope (Applied Precision, Issaquah,WA), and deconvolved using
SoftWoRx deconvolution software (Applied Precision).
Env Western blotting
For analysis of Env expression, JC53 cells transduced with
recombinant viruses expressing HXB2, 89.6 or ADA Env, or with
recombinant virus expressing the ΔEnv mutant, were harvested at48 h post-transduction, washed in PBS, resuspended in ice-cold lysis
buffer [10 mM Tris (pH 8.0), 0.5% (vol/vol) Triton X100, 150 mM
NaCl] containing a cocktail of protease inhibitors for 20 min, followed
by centrifugation at 16,000×g for 10 min to pellet cellular debris. Cell
lysates were separated in 8.5% SDS-PAGE gels and analyzed by
Western blotting using a 1:8000 dilution of rabbit anti-gp120
polyclonal antisera as described previously (Gray et al., 2006;
Sterjovski et al., 2007). Env proteins were visualized using a
1:16,000 dilution of horseradish peroxidase-conjugated anti rabbit
IgG antibody (Amersham Scientiﬁc, Piscataway, NJ) and SuperSignal
enhanced chemiluminescence (Thermo Fisher, Rockford, IL).
Nucleotide sequence accession numbers
The new Env nucleotide sequences reported here have been
assigned GenBank accession numbers GU074012 to GU074015.
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